Literature DB >> 29850334

A Case of Invasive Sinonasal Carcinosarcoma: The Importance of Early Detection.

Jason Yuen1, Vinay Varadarajan2, Marios Stavrakas2, Samiul Muquit1, Hisham Khalil2.   

Abstract

Sinonasal carcinosarcomas represent rare neoplasms, with aggressive character and unfavourable prognosis. We present a case of extensive sinonasal carcinosarcoma extending into the anterior cranial fossa and into the orbit and also a review of the current international literature regarding this rare yet aggressive neoplasm. There is currently a lack of specific guidelines on the optimal management of sinonasal carcinosarcoma and the treatment represents a challenge for the clinician. The key message that we would like to disseminate to our colleagues is the importance of suspicion and early detection, as well as the necessity to adopt a holistic approach when counselling patients.

Entities:  

Year:  2018        PMID: 29850334      PMCID: PMC5937599          DOI: 10.1155/2018/2745973

Source DB:  PubMed          Journal:  Case Rep Otolaryngol        ISSN: 2090-6773


1. Introduction

A malignant biphasic neoplasm consisting of an epithelial (squamous) element and mesenchymal component is known as a carcinosarcoma (also known as pleomorphic carcinoma, spindle cell carcinoma, pseudosarcoma, and pseudosarcomatous squamous cell carcinoma) [1, 2] although the exact nomenclature and subclassifications are variable [3]. It is classified under squamous cell carcinoma by the World Health Organization (WHO) [4]. Carcinosarcoma may arise from any squamous epithelium (e.g., salivary glands, respiratory tract, upper aerodigestive tract, and female reproductive organs) [5], but its occurrence in the sinonasal region is extremely rare [1]. There is very little evidence available about its best management.

2. Case Presentation

A 75-year-old gentleman first presented to primary care with a three month history of left-sided headaches and diplopia. He also complained of altered taste sensation and paraesthesia in the left maxillary region. There was no history of epistaxis. The patient attended his general practitioner on multiple occasions and was given sinusitis treatment until a CT scan was finally performed due to persistence of symptoms, upon which the patient was then referred to the ENT service. He has a background history of fast atrial flutter (on bisoprolol), hypertension, polymyalgia rheumatica, benign prostatic hyperplasia, and previously excised papillary squamous cell carcinoma in the left thigh. He quit smoking 40 years prior to presentation. Otherwise, he had lived independently with WHO performance status of 1 (Karnofsky status 90). The patient underwent complete head and neck examination including flexible nasoendoscopy. There was no discreet neck lymphadenopathy. Nasoendoscopy revealed a mass down to the left inferior turbinate obscuring the left nasal cavity. He complained of diplopia on the left side on the lateral gaze with proptosis of approximately 3 mm compared to the contralateral side. Vision was 6/30 bilaterally with glasses. There was no relative afferent pupillary defect or papilloedema.

2.1. Investigations

Initial CT scan revealed an aggressive lesion in left ethmoidal and frontal sinuses, invading the left orbit and anterior cranial fossa. CT neck and thorax showed no cervical or chest lymphadenopathy. Subsequent MRI imaging also showed evidence of bone erosion with breaching of the dura in the vicinity of the left orbitofrontal cortex although there was no signal change in the brain to suggest brain invasion (Figure 1). There was destruction of left lamina papyracea. An incidental right anterior cranial fossa meningioma, distant from sinonasal lesion was also identified. This pathologic finding did not have any significant clinical relevance with the primary disease.
Figure 1

MRI head scan shows breaching of dura mater. Red arrow denotes lesion of interest. (a) Axial slide. (b) Coronal slide.

A staged whole body positron-emission tomography (PET) scan showed no other distant lesions but confirmed lesion progression through the frontal sinus. Our initial differential diagnoses were squamous cell carcinoma, carcinosarcoma, lymphoma, teratocarcinosarcoma, olfactory neuroblastoma, small cell carcinoma and alveolar rhabdomyosarcoma.

2.2. Treatment

After the diagnostic workup, the patient underwent endoscopic examination of the nose and biopsy of the lesion under general anaesthesia. Extensive disease was noted at the ipsilateral maxillary antrum. Histology revealed an extensive necrotic biphasic epithelioid, spindled malignant neoplasm in keeping with carcinosarcoma. Immunohistochemistry afterwards showed no loss of DNA mismatch repair (MMR) protein expression.

2.3. Outcome

After a successful biopsy and radiological investigative workup, the patient was discharged home. Unfortunately in the community, his preexisting comorbidities worsened, and he developed poorly controlled fast atrial flutter and urosepsis with E. Coli bacteraemia. He was readmitted for antimicrobial and supportive treatment. The patient eventually recovered and was discharged. Discussion was undertaken at the multidisciplinary meeting and with international experts in the field. The consensus is that although the disease can potentially be resected with major surgery such as craniofacial resection, due to its location and size, surgical treatment would have significant risk of bleeding, cerebrospinal fluid (CSF) leak, and meningitis. After detailed consultation and discussion about the possible treatment options including the risks of such procedures with the patient and his family, he was not keen to proceed and opted for palliative radiotherapy and symptomatic management. The radiotherapy dose delivered was 20 Gy in five days, then a two-week break and finally another 20 Gy in five days. One year after diagnosis, patient tolerated the radiotherapy and continued to lead an independent life.

3. Discussion

In the head and neck area, carcinosarcomas most frequently occur in the larynx and oral cavity, followed by the skin, tonsils, sinonasal tract, pharynx and hypopharynx [6, 7]. Histologically, they have been classified as part of a spectrum of sarcomatoid carcinomas, most of which present in late middle-aged men with a long history of tobacco use. They consist of foci of overt carcinoma admixed with areas of divergent differentiation into mesenchymal tissues [8]. Spindle cell formation is also typical in the sarcomatous component. A recent study suggested that a MET protooncogene mutation may be a prerequisite event in its pathogenesis [9]. Presenting symptoms of sinonasal carcinosarcomas typically include nasal obstruction, epistaxis, facial pain, and headache [10, 11]. These are rather nonspecific to the disease. They tend to grow rapidly, with extensive local destruction. Therefore, early diagnosis and aggressive therapy are necessary to improve the often dismal prognosis [2, 8]. In a Japanese case report of maxillary carcinosarcoma, the patient died despite intensive radiochemotherapy and total maxillectomy due to rapid tumour recurrence and metastasis. However, it appeared the carinomatous component responded to the radiochemotherapy but that was not the case with the sarcomatous component [11]. Nonetheless, aggressive treatment may not cease disease progression and improve survival. Cheong et al. [12] reported on a 61-year-old male patient who underwent total maxillectomy and modified radical neck dissection and died shortly afterwards with sternal metastasis, despite having had extensive surgery with curative intent. Table 1 shows the similar cases of sinonasal carcinosarcoma reported in the literature [1, 2, 9–31]. The optimal treatment of this disease remains undetermined. It is difficult to ascertain the effectiveness of the treatment modalities (a combination of surgery, radiotherapy, and chemotherapy) from the small number of cases available in the literature. They generally confer a poor outcome and a high recurrence rate. A recent large case-control analysis of 15 sinonasal patients in America showed an average five-year disease-specific survival of 48.5%, which is significantly poorer than controls with carcinosarcoma at other anatomical sites [5]. Therefore we advocate, when patients are operatively fit with resectable disease, they should undergo aggressive surgical treatment with adjuvant radiotherapy as an attempt to improve outcome. This is because radiotherapy alone tends to convey a less favourable outcome, and the role of chemotherapy is unclear.
Table 1

Cases of sinonasal carcinosarcoma that are reported in the literature.

NumberAge (years)/sexLocationStageTreatmentOutcomeAuthor, year
162/FMaxillary sinusNDRTNo marked improvement of the tumor, DWDMeyer and Shklar, 1957 [24]
271/MMaxillary + ethmoid sinusesT4aN0M0Preoperative RT + TM + REND about postoperative tumor condition, death due to intracerebral abscess at postoperative periodFeinmesser et al., 1982 [16]
365/FMaxillary sinusNDTM + RTLR, DWD 8 months laterAmpil, 1985 [14]
457/F, (postradiation)Nasoethmoid sinusNDTumor excision, ethmoidectomy and turbinectomyLR 5 months after surgery, outcome uncertainHafiz et al., 1987 [17]
560/MNasomaxillary sinusT3N0M0TM + RT + CTLR, DWD 2 months later (diffuse metastasis in lung and brain)Sonobe, 1989 [11]
653/MMaxillary + ethmoid sinusesT4aN0M0TM + craniofacial resection + RT + CTDisease free after 9 monthsShindo et al., 1990 [2]
781/FMaxillary sinusT3N0M0TM + RT + 2nd operationLR, DWD 3 months after second operationSanabre et al., 1998 [27]
847/MMaxillary sinusNDPM+RTLR, DWD after 1 yearFuruta et al., 2001 [10]
954/MMaxillary sinusT3N3M0RT + CTDWD 4 months; possibly from lung metastasisHoward et al., 2007 [19]
10 case series (19 cases)Mean age at diagnosis 54 (range, 42–66)Male 11Female 8Sinonasal track, unclear exact locationsT1/2 3T3/4 16N0 19M0 19Surgery alone 2Surgery and RT7, RT alone 2CT + RT 2Mean follow-up 38 months (6–40)5 with disease at last follow-up0 death at follow-upDoshi et al., 2010 [15]
1175/MNasal cavityT4N0M0Surgery + CT + RTDisease-free after 5 yearsTerada and Kawasaki, 2011 [30]
1260/MMaxillary sinus and nasal cavityUnclearCT + RTDWD after 9 monthsTerada, 2011 [29]
1329/FNasopharyngealT1N2cM0RTClinically free-of-disease 2 months after RTLim et al., 2012 [22]
1460/MMaxillary + ethmoid sinusesT3N0M0TM + RT + CTLR, FLMoon, 2013 [1]
1529/MNasal cavityT2N0M0SurgeryDisease-free after 6 monthsGupta, 2013 [32]
1652/MFrontal, sphenoid, ethmoid, and maxillary sinusesT4aN0M0TM + RT + CTLRAlem and AlNoury, 2014 [13]
1761/MMaxillary sinusT4aN2cM1TM with modified neck dissectionDWD shortly after surgery with sternal metastasisCheong et al., 2014 [12]
18 case series (15 cases)Mean age at diagnosis 60.3 (SD, ±21.3)Male 6Female 9Nasal cavity 7Maxillary sinus 5Ethmoid sinus 1Frontal sinus 1Sphenoid sinus 1T1/2 3T3/4 10TX 2N0 9N+ 0NX 6M0 14M1 0MX 1Surgery alone 3surgery and RT 7RT alone 4No therapy 1Five-year disease-specific survival of 48.5%Patel et al., 2015 [5]
1966/MMaxillary sinusT3N0M0PM + RT + CTLR, DWD 10 months after initial presentationAndo et al., 2015 [9]
2078/FEthmoid sinusT4N0M0Surgery + RTDisease-free after 36 monthsIqbal et al., 2015 [20]
2166/MMaxillary sinusRecurrencePalliativeDWD after 12 months
2268/MMaxillary sinusRecurrencePalliativeDWD after 1 month
2346/MMaxillary sinusT4N0M0PalliativeDWD after 5 months
2454/MSphenoid sinusT4 N and M unclearSurgery + CT + RTDWD after 12 monthsLiu et al., 2016 [23]
2555/MMaxillary sinusT4aN0M0RTNo significant effect, died 4 months after initial examinationHasnaoui et al., 2017 [18]
2635/FMaxillary sinusT4N0M0PM + CT + RTDWD after 12 monthsSoltani et al., 2018 [28]
2775/MEthmoid + frontal sinusesT4aN0M0RTRemained independent after 12 monthsOur case, 2018

ND, not described; RT, radiation therapy; DWD, dead with disease; TM, total maxillectomy; RE, removal of eye; LR, local recurrence; CT, chemotherapy; PM, partial maxillectomy; FL, follow-up loss; LNs, lymph nodes.

Since the optimal management of carcinosarcoma remains uncertain, it is intuitive to study a related but separate (also highly aggressive) entity known as teratocarcinosarcoma [26, 33–35]. This tumour type also includes a component of neuroectodermal tissue and is much more prevalent in the medical literature. According to a recent systemic review of 49 patients, it is recommended that optimal treatment involves radical surgical resection followed by radiation therapy [25]. If more doctors are aware of this condition and the associated presenting symptoms, perhaps earlier diagnoses can be made. Therefore, patients may potentially get the option of a curative total resection, since the invasion of the skull base and surrounding structures is a poor prognostic factor. In conclusion, sinonasal carcinosarcomas represent rare neoplasms, with aggressive character and unfavourable prognosis. Here we present a case of extensive sinonasal carcinosarcoma extending into the anterior cranial fossa and into the orbit and also a review of the current international literature regarding this rare yet aggressive neoplasm. There is currently a lack of specific guidelines on the optimal management of sinonasal carcinosarcoma, and the treatment represents a challenge for the clinicians. The key message that we would like to disseminate to our colleagues is the importance of suspicion and early detection, as well as the necessity to adopt a holistic approach when counselling patients.
  31 in total

1.  Maxillary carcinosarcoma: Identification of a novel MET mutation in both carcinomatous and sarcomatous components through next generation sequencing.

Authors:  Mizuo Ando; Yuki Saito; Teppei Morikawa; Go Omura; Kenya Kobayashi; Ken Akashi; Masafumi Yoshida; Yasuhiro Ebihara; Chisato Fujimoto; Masashi Fukayama; Tatsuya Yamasoba; Takahiro Asakage
Journal:  Head Neck       Date:  2015-07-06       Impact factor: 3.147

2.  The controversial role of radiotherapy in spindle cell carcinoma (pseudosarcoma) of the head and neck.

Authors:  F L Ampil
Journal:  Radiat Med       Date:  1985 Oct-Dec

3.  Carcinosarcoma of the nose and paranasal sinuses-a case report.

Authors:  R Feinmesser; J Wiesel; E Deutsch; M Sela; I Gay
Journal:  Rhinology       Date:  1982-09       Impact factor: 3.681

4.  Spindle cell carcinoma of the nasal cavity.

Authors:  Tadashi Terada; Taiji Kawasaki
Journal:  Int J Clin Oncol       Date:  2010-09-14       Impact factor: 3.402

5.  Carcinosarcoma of the nasal cavity and paranasal sinuses.

Authors:  M L Shindo; R B Stanley; M T Kiyabu
Journal:  Head Neck       Date:  1990 Nov-Dec       Impact factor: 3.147

6.  A case-control analysis of survival outcomes in sinonasal carcinosarcoma.

Authors:  Tapan D Patel; Alejandro Vázquez; Max A Plitt; Soly Baredes; Jean Anderson Eloy
Journal:  Am J Otolaryngol       Date:  2014-10-31       Impact factor: 1.808

7.  Right maxillary sinus sarcomatoid carcinoma (sarcomatoid/spindle cell carcinoma).

Authors:  Scott N Howard; William R Bond; In Soon Hong; Robert D Foss
Journal:  Otolaryngol Head Neck Surg       Date:  2007-08       Impact factor: 3.497

8.  A rare case of nasopharyngeal carcinosarcoma.

Authors:  A L Lim; Z Zahirrudin; K C Pua
Journal:  Med J Malaysia       Date:  2012-08

Review 9.  True carcinosarcoma of the maxillary sinus.

Authors:  H Sonobe; K Hayashi; K Takahashi; Y Ohtsuki; S Kishimoto; H Saito; I Honjo
Journal:  Pathol Res Pract       Date:  1989-10       Impact factor: 3.250

10.  Spindle cell carcinoma of the nasal cavity.

Authors:  Sachin Gupta; Dominick Santoriello; Rosemary Wieczorek; Mark D De Lacure
Journal:  Rare Tumors       Date:  2013-05-02
View more
  2 in total

1.  A rare case of invasive sinonasal carcinosarcoma.

Authors:  Eduardo Luis de Souza Cruz; Antonia Taiane Lopes de Moraes; Francisco de Souza Neves Filho; José Thiers Carneiro Junior; Bruno Thiago Cruz E Silva; Victor Angelo Martins Montalli; Sérgio de Melo Alves Júnior; João de Jesus Viana Pinheiro
Journal:  Int J Surg Case Rep       Date:  2020-05-07

2.  Head and Neck Sarcomas-clinicopathological Findings, Treatment Modalities and Its Outcome - A Retrospective Study.

Authors:  Hari Ram; Satish Kumar; S N Singh; Pramod Kumar; Geeta Singh; Roop Ganguly; Mala Sagar; Debraj Howlader
Journal:  Ann Maxillofac Surg       Date:  2022-02-01
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.